BofA revises its stance on a pair of hepatitis-C drugmakers, raising Achillion Pharma...

BofA revises its stance on a pair of hepatitis-C drugmakers, raising Achillion Pharma (NASDAQ:ACHN) to Buy and cutting Idenix Pharma (NASDAQ:IDIX) to Neutral. The firm is more optimistic on the market potential for ACHN’s hepatitis-C drug combo, and hikes its share price target to $13 from $7. But IDIX faces difficulties after the FDA placed a clinical hold on one of its hep-C treatments. ACHN +13.5%, IDIX -5.5% premarket.